Discovery Analysis of TCGA Data Reveals Association between Germline Genotype and Survival in Ovarian Cancer Patients
暂无分享,去创建一个
Rosemary Braun | Qing-Rong Chen | Richard Finney | Daoud Meerzaman | Michael Edmonson | Ying Hu | Kenneth Buetow | Chunhua Yan | K. Buetow | M. Edmonson | Ying Hu | Qingrong Chen | Chunhua Yan | D. Meerzaman | R. Braun | R. Finney
[1] C. Redman,et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. , 1989, British Journal of Cancer.
[2] J. Krischer,et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.
[3] A. Berchuck,et al. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC) , 2012, Journal of internal medicine.
[4] G. Pazour,et al. Identification of predicted human outer dynein arm genes: candidates for primary ciliary dyskinesia genes , 2005, Journal of Medical Genetics.
[5] Robert Brown,et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Benítez,et al. Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis , 2009, British Journal of Cancer.
[7] Jinghui Zhang,et al. Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). , 2007, Genome research.
[8] J. Lancaster,et al. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. , 2010, American journal of obstetrics and gynecology.
[9] M. Nishiyama,et al. Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels , 2011, Breast Cancer.
[10] Joe W. Gray,et al. Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome , 2012, PloS one.
[11] N. Paneth,et al. Factors associated with small head circumference at birth among infants born before the 28th week. , 2010, American journal of obstetrics and gynecology.
[12] Xiaoyong Wang. Fresh platinum complexes with promising antitumor activity. , 2010, Anti-cancer agents in medicinal chemistry.
[13] E. Gamazon,et al. Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility , 2012, Molecular Cancer Therapeutics.
[14] P. Rose,et al. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.
[15] Kenneth H. Buetow,et al. Large-scale analysis of non-synonymous coding region single nucleotide polymorphisms , 2004, Bioinform..
[16] Yurii S. Aulchenko,et al. BIOINFORMATICS APPLICATIONS NOTE doi:10.1093/bioinformatics/btm108 Genetics and population analysis GenABEL: an R library for genome-wide association analysis , 2022 .
[17] Martin Krapcho,et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .
[18] David I. Smith,et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.
[19] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[20] G. Mills,et al. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer , 2011, Journal of experimental & clinical cancer research : CR.
[21] D. Hirsch,et al. Arf and its many interactors. , 2003, Current opinion in cell biology.
[22] A. W. Prestayko,et al. Cisplatin (cis-diamminedichloroplatinum II). , 1979, Cancer treatment reviews.
[23] A. Whittemore,et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.
[24] A. Skubitz,et al. Differential gene expression identifies subgroups of ovarian carcinoma. , 2006, Translational research : the journal of laboratory and clinical medicine.
[25] M. Jakupec,et al. Tumour-inhibiting platinum complexes--state of the art and future perspectives. , 2003, Reviews of physiology, biochemistry and pharmacology.
[26] Stephen J O'Brien,et al. Accounting for multiple comparisons in a genome-wide association study (GWAS) , 2010, BMC Genomics.
[27] K. Matsuo,et al. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay , 2010, American journal of clinical oncology.
[28] Eleazar Eskin,et al. Rapid and Accurate Multiple Testing Correction and Power Estimation for Millions of Correlated Markers , 2009, PLoS genetics.
[29] Steven Henikoff,et al. SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..
[30] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[31] D. Harrington. A class of rank test procedures for censored survival data , 1982 .
[32] Il-Jin Kim,et al. Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays , 2004, Clinical Cancer Research.
[33] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[34] J. Chang-Claude,et al. Role of genetic polymorphisms and ovarian cancer susceptibility , 2009, Molecular oncology.
[35] Adrian E. Raftery,et al. Model-Based Clustering, Discriminant Analysis, and Density Estimation , 2002 .
[36] Gudmundur A. Thorisson,et al. The International HapMap Project Web site. , 2005, Genome research.
[37] H. Kwon,et al. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells , 2010, Journal of Cancer Research and Clinical Oncology.
[38] K. Lange,et al. Prioritizing GWAS results: A review of statistical methods and recommendations for their application. , 2010, American journal of human genetics.
[39] S. Seiff. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm , 1992 .
[40] Brooke L. Fridley,et al. Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients , 2011, Clinical Cancer Research.
[41] M. Tang,et al. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. , 2005, Human reproduction.
[42] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[43] G. Moreno-Bueno,et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance , 2007, Breast Cancer Research and Treatment.
[44] S. Hauptmann,et al. Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival , 2008, Clinical Cancer Research.
[45] Jason B. Nikas,et al. Mathematical Prognostic Biomarker Models for Treatment Response and Survival in Epithelial Ovarian Cancer , 2011, Cancer informatics.
[46] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.